MOTS C is a recurring topic in our peptide coverage. This hub collects every article tagged MOTS C, newest first, each evidence-graded and tied to real, verifiable sources.
Epitalon, MOTS-c, humanin and FOXO4-DRI are marketed as telomere-lengthening, anti-aging peptides. We grade the real evidence — replicated cell-culture data, animal healthspan signals, and the total absence of a qualifying human anti-aging trial.
A clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.
A clinical-evidence ranking of the peptides marketed for insulin sensitivity and blood-sugar control — the incretin drugs that actually work in human RCTs, and the 'mitochondrial' research peptides that do not yet.
A clinical, evidence-first review of the peptides marketed for fatigue and low energy — elamipretide (SS-31), thymosin alpha-1, MOTS-c, CJC-1295 and ipamorelin. The blunt headline: no peptide has a positive fatigue RCT in healthy people.
An evidence-graded review of the peptides marketed for endurance and aerobic performance — elamipretide (SS-31), MOTS-c and AOD-9604. The honest 2026 verdict: no peptide is proven to raise VO₂max or race performance in healthy humans, the category is preclinical-dominant, and MOTS-c is WADA-banned at all times.
A clinical, evidence-first look at the peptides marketed for ME/CFS — thymosin alpha-1, elamipretide (SS-31), MOTS-c and cerebrolysin. The honest headline: no peptide has a completed CFS efficacy trial.
An evidence-first ranking of the peptides most studied for aging and healthspan — elamipretide, GHK-Cu, thymalin, epitalon and MOTS-c — separating real human data from rodent and in-vitro hype.
A clinical monograph on the mitochondrial-derived peptide (MDP) axis — MOTS-c, humanin and the small humanin-like peptides (SHLP). One coherent mechanism, three very different maturity tiers, and zero approved human therapies.
A clinical monograph on MOTS-c — the 16-amino-acid mitochondrial-derived peptide marketed as an 'exercise mimetic' and metabolic regulator. Striking rodent data, no completed human efficacy trial, and an unsettled 2026 legal status.
MOTS C is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged MOTS C, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.